Anemia and Patient‐Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real‐World Observational Study
Esther Natalie Olíva, Antonio M Risitano, Eros Di Bona, Alessandro M. Vannucchi et autres
0 citationseJHaem
Luana Marano
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
59Publications signalées
1105Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Complement system in diseasesHematopoietic Stem Cell TransplantationMultiple Myeloma Research and TreatmentsBlood groups and transfusionProtein Degradation and Inhibitors
Publications récentes
Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT ‐ SAAWP RACE Study
Antonio M. Risitano, Simona Iacobelli, Austin Kulasekararaj, Marleen van Os et autres
0 citationsAmerican Journal of Hematology
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study
Anna Paola Iori, Antonio De Vivo, Eros Di Bona, Giovanni Caocci et autres
0 citationsAnnals of Hematology
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies
Danilo De Novellis, Salvatore Palmieri, Stefano Rocco, Daniele Derudas et autres
0 citationsAnnals of Hematology
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
Antonio M. Risitano, Austin Kulasekararaj, Phillip Scheinberg, Alexander Röth et autres
12 citationsThe Lancet Haematology
An Italian Real-world Multicenter Study of Patients with Refractory/Relapsed Functional High-Risk Multiple Myeloma Patients treated with Second-Line Therapies
Danilo De Novellis, Salvatore Palmieri, Stefano Rocco, Daniele Derudas et autres
0 citationsResearch Square
The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment
Esther Natalie Olíva, Antonio M. Risitano, Eros Di Bona, Alessandro Maria Vannucchi et autres
3 citationsBlood
Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results
Bruno Fattizzo, Anna Paola Iori, Antonio De Vivo, Elisabetta Metafuni et autres
1 citationBlood
Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
Antonio M. Risitano, S. Iacobelli, Austin Kulasekararaj, Marleen van Os et autres
1 citationBlood
Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti‐ C5 therapy: A lesson not to be forgotten
Antonio M. Risitano, Camilla Frieri, Luana Marano, Eleonora Urciuoli et autres
5 citationsAmerican Journal of Hematology
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Danilo De Novellis, Daniele Derudas, Donatella Vincelli, Raffaele Fontana et autres
8 citationsEuropean Journal Of Haematology
P-388 Clinical Efficacy of Isatuximab Plus Carfilzomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: An Italian Real-Life Multi-Center Retrospective Experience
Danilo De Novellis, Daniele Derudas, Raffaele Fontana, Iolanda Donatella Vincelli et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.